- Research Resources
- Conferences & Seminars
- MD Anderson at SITC
- SITC Program
MD Anderson has numerous presentations throughout the SITC program. Note: All times are listed in Eastern Time.
MD Anderson has numerous presentations throughout the SITC program. Note: All times are listed in Eastern Time.
Thursday, November 6
Primer on Tumor Immunology and Cancer Immunotherapy™
Session III: Effector Cell Redirection Therapy
1:45–3:30 p.m.
Maryland Ballroom AB
Talk: The Role of CAR NK and NK Cell Engagers in Cancer Immunotherapy
Presenter: May Daher, M.D.
Talk: Bispecific T Cell Engagers
Presenter: Sumit Subudhi, M.D., Ph.D.
Friday, November 7
Session 102: Keynote Address
8:20–9:10 a.m.
Potomac Ballroom
Keynote: Targeting the Microbiome to Promote Health and End Cancer
Presenter: Jennifer Wargo, M.D.
Concurrent Session 105a: Rapid Oral Abstract Session - Basic
12:30–1:30 p.m.
Maryland Ballroom A
Abstract 709: A novel mouse model to investigate the impact of B cell-driven immunity in immunotherapy-treated non-small cell lung cancer
Presenter: Alessandra Vaccaro, Ph.D.
Concurrent Session 105b: Rapid Oral Abstract Session - Clinical
12:30–1:30 p.m.
Maryland Ballroom CD
Co-chair: Adam Grippin, M.D., Ph.D.
Concurrent Session 106c: Immunoprevention, Immune Interception
1:45–3:25 p.m.
Maryland Ballroom CD
Co-chair: Jianjun Zhang, M.D., Ph.D.
Talk: Reprogramming the Immune Microenvironment to Intercept Lung Adenocarcinoma Precancer
Presenter: Jianjun Zhang, M.D., Ph.D.
Concurrent Session 107b: Modulation of Anti-Tumor Immunity by Nerves and Neurotransmitters
3:55–5:35 p.m.
Maryland Ballroom AB
Talk: Clinical Perspective of Neuroimmunology
Presenter: Moran Amit, M.D., Ph.D.
Saturday, November 8
Session 203: Imaging, Radiomics, and Integrated Biomarkers in IO
9:25–11:15 a.m.
Potomac Ballroom
Talk: Future Usage of Radiomics in IO: From Phase I Neoadjuvant to Clinically Advanced Disease
Presenter: Stéphane Champiat, M.D., Ph.D.
Concurrent Session 207d: Oral Abstract Session
3:30–5:10 p.m.
National Harbor 2-3
Abstract 419: SARS-CoV-2 mRNA vaccines sensitize immunologically “cold” tumors to immune checkpoint blockade
Presenter: Adam Grippin, M.D., Ph.D.
Abstract 1228: Immune escape through oncogene-mediated editing of the HLA-ligandome
Presenter: Dustin McCurry, M.D.
Sunday, November 9
Session 301: Presidential Session
8:05-9:30 a.m.
Potomac Ballroom
Abstract 676: Lymphatic-sparing immunoradiotherapy reprograms migratory dendritic cells to drive tumor rejection via the sentinel lymph node
Presenter: Robert Saddawi-Konefka, M.D., Ph.D.
Posters
Posters are displayed in Exhibit Halls AB on Friday, Nov. 7 (10 a.m.–7 p.m.) and Saturday, Nov. 8 (10 a.m.–6:35 p.m.). Presenters of odd-numbered posters will be available Friday (12:15–1:45 p.m. and 5:35–7 p.m.), and presenters of even-numbered posters will be available Saturday (12:15–1:45 p.m. and 5:10–6:35 p.m.).
Friday, Nov. 7
Abstract 153
Association of candidate tertiary lymphoid structures in baseline tumor tissue with response to ipilimumab in patients with metastatic castration-resistant prostate cancer (mCRPC)
Presenting author: Bilal Siddiqui, M.D.
Abstract 191
Tumor microenvironment changes after treatment with avelumab combinations in patients with advanced solid tumors
Presenting author: Nejla Ozirmak Lermi
Abstract 241
Off-the-shelf bioengineered cell therapies to treat invasive fungal infections in cancer patients
Presenting author: Pappanaicken Kumar, Ph.D.
Abstract 255
Noninvasive Tracking of IL13Rα2 CAR-T Cells with ImmunoPET Reveals Spatiotemporal Dynamics and Persistence in a Melanoma Model
Presenting author: Hamid Reza Mirzaei, Ph.D.
Abstract 507
Clinical Outcomes of Platinum Doublet Chemotherapy Combined with Dual Checkpoint Inhibitors After Primary Resistance to Dual Checkpoint Inhibitor Therapy: Results from the LONESTAR Study
Presenting author: Mehmet Altan, M.D.
Abstract 569
A Phase 1/2 Study of KSQ-004EX: Autologous Tumor Infiltrating Lymphocytes, Engineered to Inactivate Genes Encoding SOCS1 and Regnase-1, in Patients with Select Advanced Solid Tumors
Presenting author: Rodabe Amaria, M.D.
Abstract 657
Targeting Glycolysis by Pramlintide Suppresses Tumor Growth in Preclinical Models of Ewing Sarcoma and Offers Opportunities for Combination with Immunotherapy
Presenting author: Nancy Gordon, M.D.
Abstract 767
Type 1 Conventional Dendritic Cell Therapy Coordinates Tumor Control in Murine Melanoma
Presenting author: Morgan Riba, M.D.
Abstract 1057
Early Targeted Biologics Are Associated with Improved Clinical Outcomes in Immune-Related Myocarditis, Myositis, and Myasthenia Gravis
Presenting author: Lily Chen, M.D.
Abstract 1107
A Unified Framework for Cross-Platform Spatial Omics Analysis and Deep Spatial Profiling
Presenting author: Yunhe Li
Saturday, Nov. 8
Abstract 110
Quantifying a pan-cancer immune temperature to predict patient-specific treatment response and outcome
Presenting author: Awino Ojwang', Ph.D.
Abstract 308
Arming Oncolytic Adenoviruses with Immune Stimulators: Enhancing CAR T Cell Therapy for Malignant Primary and Metastatic Brain Tumors
Presenting author: Hong Jiang, M.D.
Abstract 368
Time-lapse analysis of TCR-T cells highlights heterogeneity and kinetics of responses upon antigen stimulation
Presenting author: Amanda Montoya
Abstract 458
Mapping and quantifying tumor cell killing rates in 3D to determine the bottlenecks to durable responses to checkpoint blockade
Presenting author: Kenneth Hu, Ph.D.
Abstract 462
Dysregulated enhancer landscape and resistance to immunotherapy by SMARCA4 mutation in lung cancer.
Presenting author: Yonathan Lissanu, M.D., Ph.D.
Abstract 532
A phase 1 dose escalation and dose expansion trial of NP-101 in patients with advanced solid tumors
Presenting author: Aung Naing, M.D.
Abstract 584
Nanomechanical Signatures Predict Response to Combination Immunotherapy and Low Dose Radiation Therapy in Advanced Solid Tumors
Presenting author: Nahum Puebla Osorio, D.V.M., Ph.D.
Abstract 672
Immune Activation with Plinabulin Promotes Monocyte-Macrophage Responses Combining Radiation with Immune Checkpoint Blockade (ICB) in ICB-Relapsed/Refractory Tumors
Presenting author: Steven Lin, M.D., Ph.D.
Abstract 760
Tumor oxidative metabolism exhibits atypical dependence on two mitochondrial complex I subunits that are dispensable for T cell function
Presenting author: Krithikaa Rajkumar Bhanu, Ph.D.
Abstract 876
Immune effects of radiation dose enhancement using internalized gold nanoparticles
Presenting author: Bhoomika Muruvekere Lakshmisha
Abstract 1064
Clinical and prognostic characterization of high-grade neurologic immune-related adverse events in patients with urinary cancers
Presenting author: Mohammad Jad Moussa, M.D.
Abstract 1246
A single-cell atlas of ovarian cancer reveals tumor microenvironmental heterogeneity and cancer cell plasticity in response to therapies
Presenting author: Yibo Dai
Abstract 1288
TME and Molecular Characteristics of KRASQ61 Mutated Gastrointestinal Malignancies and Clinical Outcomes
Presenting author: Dan Zhao, M.D., Ph.D.
Abstract 1322
IDP-023 Allogeneic g-NK-cells +/- Anti-CD38 Monoclonal Antibody for the Treatment of Relapsed/Refractory Multiple Myeloma: Safety, Efficacy and Determination of Recommended Phase 2 Dose
Presenting author: Krina Patel, M.D.
Abstract 1338
Multi-cohort phase II study of autologous centrally manufactured tumor infiltrating lymphocytes
Presenting author: Amir Jazaeri, M.D.
Abstract 1348
Final Overall Survival Analysis of HARMONi-A Study Comparing Ivonescimab Plus Chemotherapy to Chemotherapy Alone in Patients With EGFR+ NSCLC Progressed on EGFR-TKI Treatment
Presenting author: Xiuning Le, M.D., Ph.D.
Give Now
Your gift will help make a tremendous difference.
Research Areas
Find out about the four types of research taking place at MD Anderson.
Subscribe
Get the latest information on our cancer breakthroughs.